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http://dx.doi.org/10.1016/j.jaip.2016.02.014METHODS: This post hoc analysis from a 12-week study
(NCT00652002) assessed patients aged 12 years or more with
moderate-to-severe asthma randomized to twice-daily budeso-
nide/formoterol (BUD/FM) via pressurized metered-dose
inhaler (pMDI) 320/9 mg, BUD pMDI 320 mg, FM 9 mg via dry-
powder inhaler, or placebo. FAO status was assessed post-
bronchodilator at screening and after study drug administration
at weeks 2, 6, and 12 via the forced expiratory volume in 1
second to forced vital capacity (FEV1/FVC) ratio < lower limit of
normal (LLN) (FAOD) or ‡ LLN (FAOL). Patients with
persistent FAOL and FAOD retained their screening FAO
status at all visits. Patients with inconsistent FAO changed cat-
egories at least once during the study. Assessments included early
withdrawal due to predeﬁned worsening asthma events (PAEs),
lung function, and symptoms.
RESULTS: Of 386 patients, 29% had persistent FAOD, 31%
inconsistent FAO, and 40% persistent FAOL. PAEs were lowest
in the FAOL group overall and with BUD/FM treatment in
patients with FAOD and inconsistent FAO. Baseline
demographics and treatment responses of the inconsistent FAO
group were most similar to the FAOD group. The greatest
improvements in asthma control days and use of rescue
medications were seen with BUD/FM treatment, regardless of
FAO status.
CONCLUSIONS: Approximately one third of patients with
moderate-to-severe asthma in this study had inconsistent FAO,
and their treatment responses were most similar to patients with
FAOD. Regardless of FAO status, patients treated with BUD/
FM experienced the most improved treatment responses and
fewest withdrawals due to PAEs.  2016 The Authors. Pub-
lished by Elsevier Inc. on behalf of the American Academy of705
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BUD/FM- Budesonide/formoterolDPI- Dry-powder inhaler
FAO- Fixed airﬂow obstructionFEV1/FVC- Ratio of forced expiratory volume in 1 second to forced
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PAEs- Predeﬁned worsening asthma events
pMDI- Pressurized metered-dose inhalerAllergy, Asthma & Immunology. This is an open access
article under the CC BY-NC-ND license (http://
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Immunol Pract 2016;4:705-12)
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Asthma is a chronic inﬂammatory disorder associated with
bronchial hyperresponsiveness, which leads to variable and recurring
episodes of wheezing, breathlessness, chest tightening, and cough-
ing.1 Some patients, often those with severe asthma, demonstrate an
expiratory airﬂow obstruction that is not completely reversible
despite optimal treatment.1-3 The presence of not fully reversible or
ﬁxed airﬂow obstruction (FAO) is generally attributed to airway
inﬂammation resulting in remodeling,1 which encompasses struc-
tural changes including increased smooth muscle mass, loss of
epithelial integrity, basement membrane thickening, subepithelial
ﬁbrosis, submucosal gland hyperplasia, decreased cartilage integrity,
and increased airway vascularity.4-7
Remodeling is associated with greater disease burden and
poorer clinical outcomes.6 Proposed causes of FAO in asthma
include insufﬁcient treatment, persistence of inﬂammation,
active smoking, neutrophilic inﬂammation that may be less
responsive to treatment, and the potential development of steroid
resistance.7-9 Clinical factors that have been associated with FAO
in asthma include the presence of eosinophilia, elevated immu-
noglobulin E, history of smoking, asthma onset more than 25
years of age, duration of asthma, aging, and the degree of airway
hyperresponsiveness.2,10
There is no accepted deﬁnition of FAO in asthma. Persistent
airﬂow limitation in chronic obstructive pulmonary disease is
deﬁned as the ratio of forced expiratory volume in 1 second to
forced vital capacity (FEV1/FVC) below a postbronchodilator
threshold of 0.70,11 whereas others have used an FEV1/FVC that
is lower than the lower limit of normal (LLN) after optimal
treatment.12 The LLN deﬁnition is derived from reference
equations speciﬁc to the population under study, which take into
account age, gender, and ethnicity.13,14 A previous descriptive
analysis characterized FAO using the LLN-based deﬁnition in
patients with mild-to-moderate or moderate-to-severe asthma.15
In that analysis, patients with FAO had greater impairment than
patients without FAO overall, and they appeared to have an
enhanced response to budesonide/formoterol (BUD/FM) com-
bination therapy; however, interpretation was limited because
FAO status was assessed only on a single occasion at screening.15
Although the presence of FAO is widely recognized by practicing
clinicians and asthma researchers, little is known about the sta-
bility of FAO status over time except that progressive airﬂow
obstruction has been linked with an increased risk of mortality.16Despite the fact that variable airﬂow limitation is a hallmark of
asthma,1 inconsistent FAO status is not deﬁned.
Here, we present a post hoc analysis of the stability of FAO
status during a 12-week study of adults and adolescents with
moderate-to-severe asthma.15 The objectives of this analysis were
to characterize the consistency of baseline FAO status during the
12-week treatment period and to determine whether patients
with persistent FAO, inconsistent FAO, or absence of FAO
responded differently to treatment.15 In particular, we assessed
the association between FAO status and early study withdrawal
due to predeﬁned worsening asthma events, pulmonary function,
rescue medication use, and percentage of asthma control days.METHODS
Patients, study design, and treatments
This post hoc analysis includes data from a previously reported
double-blind, double-dummy, placebo-controlled, randomized, 12-
week study conducted in patients aged 12 years or more with
moderate-to-severe, inhaled corticosteroid-dependent asthma who
were not active smokers and, if a former smoker, had a smoking
history of 10 pack-years.15,17 At screening, patients must have
demonstrated reversibility of 12% and 0.20 L FEV1 from the
baseline value within 15-30 minutes after the administration of a
standard dose of short-acting bronchodilator.17
Asthma was deﬁned according to American Thoracic Society
criteria.18 Patients were required to have used moderate- to high-dose
inhaled corticosteroids either alone or in combination with other
asthma maintenance medications and to have a prebronchodilator
FEV1 % predicted value of45% to85% measured6 hours after
the last dose of inhaled short-acting b2 agonist and 24 hours after
taking a long-acting b2 agonist.
17 The study included a 2-week run-in
period during which patients received twice-daily BUD pressurized
metered-dose inhaler (pMDI) 160 mg and as-needed rescue albuterol
(2-4 inhalations [90 mg per inhalation]). Patients were randomized to
receive one of the following treatments twice daily: BUD/FM pMDI
320/9 mg as 160/4.5 mg  2 inhalations; BUD pMDI 320 mg as 160
mg  2 inhalations þ FM dry-powder inhaler (DPI) 9 mg as 4.5 mg 
2 inhalations (not presented in this analysis); BUD pMDI 320 mg as
160 mg  2 inhalations; FM DPI 9 mg as 4.5 mg  2 inhalations; or
placebo.17
To maintain blinding, patients in all treatment groups received
both a pMDI and a DPI containing either active treatment or pla-
cebo. Patients were eligible for randomization if they had docu-
mented daytime or nighttime asthma symptom scores >0 (where
0 indicates no symptoms and 3 indicates severe symptoms) on 3 of
7 consecutive days during the run-in period.17 Patients received peak
ﬂow meters and hand-held electronic diaries at screening, and were
instructed to use the electronic diary twice daily to record peak
expiratory ﬂow, asthma symptoms, nighttime awakenings as a result
of asthma, and rescue medication use.17
Study protocols were approved by an institutional review board
for each of the clinical sites and conducted in conformance with
guidelines for the ethical treatment of human subjects, Good
Clinical Practice, and applicable local regulations. Patients provided
written informed consent and written assent as appropriate, before
study procedures were begun.17 The study was performed in
accordance with ethical principles based on the Declaration of
Helsinki and consistent with the International Conference on
Harmonization/Good Clinical Practice and applicable regulatory
requirements.
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Patient disposition has been detailed previously.17 Treatment
outcomes were assessed based on the mean changes from baseline to
the mean during the randomized treatment period for pulmonary
function variables (predose FEV1 [L]) and daily diary-derived vari-
ables. Baseline FEV1 was deﬁned as the predose FEV1 value
measured on the day of randomization. Baseline for all diary vari-
ables was deﬁned as the mean of all run-in diary data excluding the
day of randomization. Study withdrawal because of a predeﬁned
asthma event was assessed based on predeﬁned criteria for worsening
asthma including a decrease in morning predose FEV1 of 20%
from the value at randomization or a decrease to <40% of predicted
normal; use of 12 inhalations of albuterol per day on 3 days
within any 7 consecutive days after randomization; a decrease in
morning peak expiratory ﬂow of20% from baseline (deﬁned as the
mean of all values from the 7-day period immediately preceding
randomization) on 3 days within any period of 7 consecutive days
after randomization; nighttime awakening due to asthma requiring
the use of rescue medication on 2 nights within any period of 7
consecutive days after randomization; or clinical exacerbation
requiring emergency treatment, hospitalization, or use of asthma
medication not allowed in the protocol.
Patients who experienced any of the predeﬁned criteria for
worsening asthma were automatically withdrawn from the study,
with the exception of patients who reported 2 nights with an
awakening due to asthma for whom withdrawal was at the in-
vestigator’s discretion. The analysis of patient withdrawals includes
only patients who withdrew based on predeﬁned asthma-related
events after week 2. All other noneasthma-related patient with-
drawals after week 2 were considered censored events.
Secondary efﬁcacy variables captured via electronic diary included
overall daily rescue medication use (the sum of the number of
daytime and nighttime inhalations of rescue medication from the
same calendar day) and asthma control days (a composite variable
deﬁned as a symptom-free day that was also free from daytime or
nighttime use of rescue medication).17
FAO assessments
The presence of FAO (FAOþ) was deﬁned as postbronchodilator
FEV1/FVC < LLN, and the absence of FAO (FAO) was deﬁned
as FEV1/FVC  LLN.13,15 LLN was based on gender- and race/
ethnicity-speciﬁc regression equations developed from the third
National Health and Nutrition Examination Survey (NHANES III),
which included males and females in 3 major racial and/or ethnic
groups (white, African Americans, and Mexican Americans) with an
age range of 8-80 years.14 Patients who were not in these 3 major
racial and/or ethnic groups were not included in this analysis. The
equations were extrapolated for the 1 patient aged more than 80
years.
FAO status during the treatment period was assigned based on
whether FEV1/FVC was <LLN or LLN (FAOþ and FAO,
respectively) approximately 15-30 minutes after albuterol (2e4 in-
halations [90 mg/inhalation] or up to 2.5 mg nebulized albuterol) at
screening, and 120 minutes after study drug at weeks 2, 6, and 12.
At each visit, patients were classiﬁed as either FAOþ or FAO.
“Persistent FAOþ” describes patients who were FAOþ at screening
and remained FAOþ at each study visit as deﬁned above. “Persistent
FAO” describes patients who were FAO at screening and
remained FAO at each study visit as deﬁned above. If at any visit,
the FAO status was different from the FAO status at screening, the
patient was classiﬁed as inconsistent FAO.Statistical analysis
Formal statistics were not performed in this post hoc analysis.
Data were stratiﬁed by FAO category based on the LLN deﬁnition
using descriptive statistics only. Kaplan-Meier was used for esti-
mating the probability of not having a withdrawal event.RESULTS
Patient demographics and FAO status
Of 596 randomized patients, a total of 386 were included in
this post hoc analysis. Patients excluded from the analysis included
those for whom spirometry data at all evaluation times were not
available, patients who withdrew from the study within the ﬁrst
2 weeks for any reason, and patients for whom race was not
known or standard reference values were not available for LLN
categorization. In 268 of the 386 patients (69%), FAO status was
stable throughout the study as either persistent FAO (n ¼ 155;
40%) or persistent FAOþ (n ¼ 113; 29%). The remaining 118
patients (31%) had inconsistent FAO, having changed FAO status
at least once during the course of the study (Table I).
Patient demographics, disease characteristics, and FAO status
at screening are shown in Table I. Patients with persistent FAOþ
had a greater percentage of males and longer duration of asthma
than patients with persistent FAO or inconsistent FAO. FEV1
% predicted was lower for patients with persistent FAOþ than
for patients with persistent FAO or inconsistent FAO. Use of
rescue medication at baseline was higher in the patients with
persistent FAOþ and inconsistent FAO than in the patients with
persistent FAO.
A greater percentage of patients remained FAO throughout
the treatment period when treated with BUD/FM versus any
other treatments (Figure 1). The placebo group had the lowest
percentage of patients remaining FAO throughout the treat-
ment period. Of the patients with inconsistent FAO, 84 were
reclassiﬁed from FAO at baseline to FAOþ during the treat-
ment period, and 34 from FAOþ to FAO. Of the 84 patients
who were reclassiﬁed from FAO to FAOþ, 33% received
placebo, 24% received FM, 30% received BUD, and the lowest
percentage (13%) received BUD/FM. Of the 34 patients who
were reclassiﬁed from FAOþ to FAO, more patients received
BUD/FM (41%) than BUD (24%), FM (24%), or placebo
(12%). Sample sizes between treatment groups were different
due to premature withdrawals, and therefore data points were not
available to deﬁne FAO status over the entire course of the
12-week trial for all patients.
Withdrawal due to predefined events and FAO
status
Probability of withdrawal due to predeﬁned asthma events
according to FAO status is shown in Figure 2. When combining
patients across treatment arms, patients with persistent FAO
had the fewest number of withdrawals due to predeﬁned asthma
events (Figure 2, A) compared with patients with persistent
FAOþ (Figure 2, B) or inconsistent FAO (Figure 2, C).
Over the course of the study, the percentage of withdrawals was
greater for FM alone (33 of 98 [34%]) and placebo (34 of 89
[38%]) compared with BUD/FM (9 of 107 [8%]) and BUD
alone (16 of 92 [17%]). Withdrawals in patients with persistent
FAOþ were fewest with BUD/FM versus the other treatments
(Figure 2, B). During the ﬁrst 6 weeks of the study, the majority
of withdrawals occurred among patients with persistent FAOþ
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FIGURE 1. Distribution of FAO status throughout the treatment period. BUD, Budesonide; FAO, fixed airflow obstruction; FM, formoterol.
TABLE I. Patient demographic and screening disease characteristics by FAO category (LLN definition)
Persistent FAOL (n [ 155) Persistent FAOD (n [ 113) Inconsistent FAO (n [ 118) Total (N [ 386)
Age, y 42.6 (16.5) 41.7 (15.2) 40.7 (14.8) 41.8 (15.6)
Sex, n (%)
Male 50 (32.3) 49 (43.4) 41 (34.7) 140 (36.3)
Female 105 (67.7) 64 (56.6) 77 (65.3) 246 (63.7)
BMI, kg/m2 30.5 (8.6) 29.0 (6.6) 29.7 (7.0) 29.8 (7.6)
Duration of asthma, y 19.2 (16.0) 28.4 (15.6) 21.6 (13.9) 22.6 (15.7)
% Reversibility 21.7 (14.5) 23.1 (12.0) 22.6 (11.5) 22.4 (12.9)
Predose FEV1 (L)* 2.3 (0.6) 2.1 (0.7) 2.2 (0.7) 2.2 (0.7)
FEV1 % predicted†,z 72.7 (9.1) 62.8 (10.3) 67.9 (10.6) 68.3 (10.7)
Predose FVC (L)* 3.1 (0.9) 3.5 (1.1) 3.3 (1.0) 3.3 (1.0)
FVC % predicted†,z 81.6 (12.0) 85.9 (12.8) 85.5 (13.1) 84.0 (12.7)
Baseline ICS dose, n (%)
Moderatex 118 (30.6) 76 (19.7) 87 (22.5) 281 (72.8)
Highjj 37 (9.6) 37 (9.6) 31 (8.0) 105 (27.2)
Rescue medication use, inh/d{ 2.0 (2.1) 2.9 (2.6) 2.4 (2.4) 2.4 (2.4)
% Asthma control days{,# 6.5 (14.9) 8.6 (18.6) 8.3 (18.4) 7.7 (17.1)
BMI, Body mass index; FAO, ﬁxed airﬂow obstruction; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; inh/d, inhalations per day; ICS, inhaled
corticosteroid; LLN, lower limit of normal; NHANES III, third National Health and Nutrition Examination Survey.
Values shown are mean (SD) unless otherwise noted.
*Baseline is deﬁned as the predose FEV1 or FVC measured on the day of randomization.
†NHANES III.
zPrebronchodilator, visit 2 (day of randomization).
xModerate ICS dose: beclomethasone dipropionate (chloroﬂuorocarbon [CFC]) 504-840 mg/d, beclomethasone dipropionate (hydroﬂuoroalkane [HFA]) 160-280 mg/d,
budesonide 400-600 mg/d, ﬂunisolide 1000-1999 mg/d, ﬂuticasone (CFC) 264-440 mg/d, ﬂuticasone (Diskus) 300-500 mg/d, or triamcinolone acetonide 800-1999 mg/d.
jjHigh ICS dose: beclomethasone dipropionate (HFA) >280 mg/d, budesonide >600 mg/d, ﬂunisolide >2000 mg/d, ﬂuticasone (CFC) >440 mg/d, ﬂuticasone (Diskus) >500 mg/d,
or triamcinolone acetonide >2000 mg/d.
{Baseline is deﬁned as the mean of all values obtained during the run-in period.
#Asthma control days are deﬁned as a composite measure of symptom-free days that were also free from daytime or nighttime use of rescue medication.
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inconsistent FAO, the fewest withdrawals were observed in the
BUD/FM and BUD treatment arms; however, the percentage of
patients with inconsistent FAO withdrawing in both of these arms
(Figure 2, C) was greater than the percentages seen with either the
persistent FAOþ (Figure 2, B) or FAO (Figure 2, A) groups.
Lung function and FAO status
Overall, BUD/FM treatment resulted in a numerically greater
improvement in mean change from baseline in predose FEV1versus FM or BUD alone in the persistent FAO and persistent
FAOþ groups (Figure 3). Over the course of the study, the FM
and placebo arms in the persistent FAOþ and inconsistent FAO
groups demonstrated a decline in mean predose FEV1 not seen in
the persistent FAO group.
Patient-reported outcomes and FAO status
A decrease in rescue medication use, measured as 0.5 in-
halations per day, was observed in patients in all treatment arms
(Figure 4). Regardless of FAO status, a numerically greater
A B
C
FIGURE 2. Withdrawals due to PAEs in patients with (A) persistent FAO, (B) persistent FAOþ, and (C) inconsistent FAO. BUD,
Budesonide; FAO, fixed airflow obstruction; FM, formoterol; PAEs, predefined worsening asthma events; PBO, placebo.
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0.5 inhalations per day were seen in the BUD/FM treatment
arm compared with all other treatments. Similarly, the greatest
increase in the percentage of asthma control days was reached in
the BUD/FM treatment arm compared with all other treatment
arms, regardless of FAO status (Figure 5). The BUD treatment
arm had similar mean changes from baseline in the percentage of
asthma control days compared with placebo for patients with
persistent FAOþ and inconsistent FAO.
DISCUSSION
Previous analyses of patients with asthma with FAO determined
their status at screening only, and did not account for the possibility
of FAO inconsistency during the course of a study.15 The present
post hoc analysis evaluated FAO status at screening as well as at
weeks 2, 6, and 12 of the study. These analyses identiﬁed an
inconsistent FAO group that is in many ways similar to thepersistent FAOþ group, including a poor response to FM alone.
The prevalence of persistent FAOþ and inconsistent FAO in this
cohort of patients with moderate-to-severe stable asthma was 60%,
which is similar to the prevalence of FAOþ asthma (range, 49%-
60%) reported in other studies of adult patients with severe or
difﬁcult-to-treat asthma.2,19 In contrast, reports in patients with
mild-to-moderate asthma using LLN criteria at screening found
only 24% of patients to be FAOþ.15 These data are consistent
with the increased incidence of an irreversible component of airﬂow
obstruction observed as the severity of asthma increases.3 Patients
with persistent FAOþ had a longer history of asthma compared
with patients with persistent FAO or inconsistent FAO, a ﬁnding
also observed in the Epidemiology and Natural History of Asthma:
Outcomes and Treatment Regimens (TENOR) study analysis of
risk factors seen for persistent airﬂow limitation.19 Patients with
FAO in the BUD/FM arm were the most stable group and least
likely to change status to FAOþ.
FIGURE 3. Predose FEV1 improvements in L by treatment and FAO status. Baseline was defined as the predose FEV1 value measured on
the day of randomization (visit 2) or the screening predose value, if no value was available at visit 2. bid, Twice daily; BUD, budesonide;
FAO, fixed airflow obstruction; FEV1, forced expiratory volume (L) in 1 second; FM, formoterol.
FIGURE 4. Percentage of responders with a 0.5 inh/d decrease in rescue medication use by treatment and FAO status. A decrease in
rescue medication use was defined as the change from baseline (mean of all values during the run-in period) to mean value during the
treatment period. bid, Twice daily; BUD, budesonide; FAO, fixed airflow obstruction; FM, formoterol; inh/d, inhalations per day.
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or <75%2 predicted) has been generally associated with greater
disease burden, poorer prognosis, and more severe asthma.19,20 In
addition, the results of a 17-year study in patients with asthma
with chronic airﬂow limitation (deﬁned as FEV1<80% predicted)
showed an increased risk of mortality,16 and the ﬁndings of a 5-
year follow-up study in patients with FAO due to either asthma
or chronic obstructive pulmonary disease (deﬁned by FEV1/FVC
<0.70) found an increased rate of decline in FEV1 and an
increased frequency of exacerbations in those patients with FAO
versus asthma controls without FAO.21 Our data support the
impact of FAO on greater disease burden, with the greatest
number of patient withdrawals due to worsening asthma-relatedevents occurring in patients with persistent FAOþ and inconsis-
tent FAO and the fewest patient withdrawals occurring in patients
with persistent FAO. Patients who had inconsistent FAO
behaved most like those patients who had persistent FAOþ, with
a similar number of withdrawals due to worsening asthma-related
events. Patients treated with BUD/FM compared with the other
study treatments had the fewest withdrawals in the FAOþ and
inconsistent FAO groups, suggesting additional beneﬁts in pre-
venting worsening asthma-related events for more severely
obstructed patients. Consistent with the greater disease burden
seen with persistent airﬂow obstruction, a level of deterioration of
predose FEV1 roughly similar to that in the placebo treatment arm
occurred in the patients with persistent FAOþ and inconsistent
FIGURE 5. Mean change in percentage of asthma control days by treatment and FAO status. An increase in the percentage of asthma
control days was defined as the mean change from baseline (mean of all run-in period values) over the double-blind treatment period. bid,
Twice daily; BUD, budesonide; FAO, fixed airflow obstruction; FM, formoterol.
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patients with persistent FAO, who had improved responses with
all treatments.
BUD/FM has been shown to reduce the need for rescue
medications in patients with moderate-to-severe asthma,17 a
beneﬁt conﬁrmed by this analysis irrespective of FAO status.
Despite a higher use of rescue medications at baseline for patients
with persistent FAOþ and inconsistent FAO versus patients with
FAO, large differences were observed between BUD/FM
treatment and placebo in the percentage of patients with a
decrease in rescue medication use of 0.5 inhalations per day for
all 3 FAO groups (between-group differences of 26.0%, 35.0%,
and 33.8%, respectively). Although pulmonary function and
symptoms do not always improve in parallel, patients improved
in both categories with BUD/FM treatment compared with
placebo regardless of FAO status. As a composite variable,
improvements in asthma control days capture the improvements
in days with no symptoms plus freedom from daytime or
nighttime use of rescue medication. Therefore, compared with
rescue medication use, the marked increase in the percentage of
asthma control days reﬂects an impact on a broader parameter of
symptomatology, and implies a broader beneﬁt.
Limitations of the analysis are the post hoc nature, the rela-
tively small subgroups, use of descriptive statistics, and the study
duration of 12 weeks. It is difﬁcult to establish a clear cause-and-
effect relationship between FAO status and treatment responses
and vice versa, and correlations are hypothetical. It may take
longer than 12 weeks to reach the maximum corticosteroid ef-
fect, and it is also possible that maximal bronchodilation was not
achieved in patients at screening and the week 2, 6, and 12
testing intervals, which could have misidentiﬁed FAO status.
Considering the short study duration, interpretation of our
ﬁndings assessing the effect of inconsistent postbronchodilator
airﬂow limitation on exacerbations is limited. Finally, because
FAO status was based on posttreatment spirometry at weeks 2, 6,
and 12, there was a limited expected bronchodilatory response
for patients receiving placebo or BUD. In addition, the ﬁndingsfrom this analysis may not be generalized to all patients with
asthma. Patients were required to show bronchodilator revers-
ibility for entry into the study, active smokers were excluded, and
pack-year history was less than 10. Thus, the data presented in
this article are valid only for certain subsets of patients with
asthma. The ﬁndings presented here could serve as a foundation
for future analyses in other subsets of patients with asthma.
CONCLUSION
The patient group identiﬁed as inconsistent FAO had baseline
demographic and disease state characteristics and responses to
treatment that were more similar to those of patients with
persistent FAOþ than patients with persistent FAO. Adult and
adolescent patients with moderate-to-severe asthma who had
persistent FAO had favorable clinical responses to FM mon-
otherapy not observed with patients who had persistent FAOþ
or inconsistent FAO. Patients with asthma treated with BUD/
FM combination therapy were most likely to retain persistent
FAO and least likely to develop inconsistent FAO. Irrespective
of FAO status, the BUD/FM treatment arms experienced the
lowest percentage of patient withdrawals due to asthma-
worsening events, the largest change in percentage of asthma
control days, and numerically a greater percentage of responders
with a decrease in rescue medication use.
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